Google
×
Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
See a full list of events and presentations as well as helpful resources covering Delcaths investors and studies in patients with metastatic ocular ...
Delcath Investor Relations: investorrelations@delcath.com. Accountants: Marcum LLP. Transfer Agent: American Stock Transfer & Trust Company, LLC
Investor Relations Contact: Ben Shamsian Lytham Partners 646-829-9701 shamsian@lythampartners.com. Cision View original content to download multimedia:https ...
Investor Presentation. (NASDAQ: DCTH). November 2012 · 2. DELCATH SYSTEMS, INC. Forward-looking Statements · 3. DELCATH SYSTEMS, INC. Our Mission · 4. DELCATH ...
Missing: relations | Show results with:relations
2 days ago · Investor Relations Contact: Ben ShamsianLytham Partners646-829-9701shamsian@lythampartners.com. DELCATH SYSTEMS, INC. Consolidated Balance ...
Mar 8, 2024 · Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System) ... Delcath Systems, Inc. (Nasdaq: DCTH) ...
(Nasdaq: DCTH), an interventional oncology company focused on the treatment of ... Delcath Investor Relations. Email: investorrelations@delcath.com. Hayden IR.
Find the latest Delcath Systems, Inc. (DCTH) stock quote, history, news and other vital information to help you with your stock trading and investing.
Missing: relations | Show results with:relations
Find annual and quearterly earnings data for Delcath Systems, Inc. Common Stock (DCTH) including earnings per share, earnings forecasts at Nasdaq.com.